1. Home
  2. MUR vs CRNX Comparison

MUR vs CRNX Comparison

Compare MUR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Murphy Oil Corporation

MUR

Murphy Oil Corporation

HOLD

Current Price

$40.94

Market Cap

4.9B

Sector

Energy

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.93

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUR
CRNX
Founded
1950
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
MUR
CRNX
Price
$40.94
$36.93
Analyst Decision
Hold
Strong Buy
Analyst Count
15
8
Target Price
$33.64
$76.63
AVG Volume (30 Days)
2.9M
1.1M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
3.41%
N/A
EPS Growth
N/A
N/A
EPS
0.72
N/A
Revenue
$2,718,823,000.00
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
$10.70
$184.67
P/E Ratio
$57.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.95
$24.10
52 Week High
$42.91
$57.99

Technical Indicators

Market Signals
Indicator
MUR
CRNX
Relative Strength Index (RSI) 64.48 46.73
Support Level $29.81 $33.23
Resistance Level N/A $45.32
Average True Range (ATR) 1.61 1.68
MACD 0.17 0.50
Stochastic Oscillator 75.55 76.62

Price Performance

Historical Comparison
MUR
CRNX

About MUR Murphy Oil Corporation

Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: